13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001727492
Total reported value
$2.1B
$2.1B
26 檔
40.1%
At the close of Q1 2026, Caligan Partners LP disclosed equity holdings valued at approximately $2.1B, spread across 26 reported holdings.
In Q1 2026, Caligan Partners LP displayed an active expansion posture, initiating 9 new positions and adding to 10 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including LQDA, RVMD, ABVX) accounted for 40.1% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LQDA | Liquidia CORP | Stock-Other | 20.39% | +10.06% | — | |
| 2 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 12.18% | +7.32% | +46.56% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 10.83% | -1.06% | +0.69% | |
| 4 | PCVX | Vaxcyte Inc | Stock-Other | 7.97% | -1.98% | +20.88% | |
| 5 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.39% | -2.86% | +26.71% | |
| 6 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 5.00% | -5.00% | EXIT | |
| 7 | EXEL | Exelixis Inc | Stock-Healthcare | 4.43% | -0.45% | — | |
| 8 | CGON | Cg Oncology Inc | Stock-Other | 4.05% | -4.05% | EXIT | |
| 9 | TNGX | Tango Therapeutics Inc | Stock-Other | 3.35% | +0.33% | -35.42% | |
| 10 | TYRA | Tyra Biosciences Inc | Stock-Other | 3.25% | -2.04% | +35.24% | |
| 11 | ADMA | Adma Biologics Inc | Stock-Healthcare | 3.03% | -0.66% | +67.85% | |
| 12 | SYRE | Spyre Therapeutics Inc | Stock-Other | 2.95% | -2.95% | EXIT | |
| 13 | LBRX | Lb Pharmaceuticals Inc | Stock-Other | 2.30% | -0.10% | — | |
| 14 | VOR | Vor Biopharma Inc | Stock-Other | 2.29% | -0.62% | +108.10% | |
| 15 | SABS | Sab Biotherapeutics Inc | Stock-Other | 2.03% | -0.57% | — | |
| 16 | IRD | Opus Genetics Inc | Stock-Other | 1.84% | -0.66% | — | |
| 17 | IVA | Inventiva SA - Adr | Stock-Other | 1.84% | -0.39% | +148.75% | |
| 18 | MBX | Mbx Biosciences Inc | Stock-Other | 1.69% | -1.17% | — | |
| 19 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.62% | +1.13% | +85.47% | |
| 20 | ANIK | Anika Therapeutics Inc | Stock-Other | 1.38% | -0.39% | — | |
| 21 | MAZE | Maze Therapeutics Inc | Stock-Other | 1.22% | -1.22% | EXIT | |
| 22 | VRCA | Verrica Pharmaceuticals Inc | Stock-Other | 0.33% | -0.06% | — | |
| 23 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.26% | +0.48% | — | |
| 24 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.20% | -0.04% | — | |
| 25 | AURA | Aura Biosciences Inc | Stock-Other | 0.10% | +1.34% | — | |
| 26 | XLO | Xilio Therapeutics Inc | Stock-Other | 0.06% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | +3.8% | +46.56% | Add |
| 2 | PCVX | Vaxcyte Inc | +1.5% | +20.88% | Add |
| 3 | VOR | Vor Biopharma Inc | +1.5% | +108.10% | Add |
| 4 | XENE | Xenon Pharmaceuticals Inc | +1.3% | +26.71% | Add |
| 5 | TYRA | Tyra Biosciences Inc | +1.2% | +35.24% | Add |
| 6 | IVA | Inventiva SA - Adr | +1.1% | +148.75% | Add |
| 7 | TNGX | Tango Therapeutics Inc | +0.6% | -35.42% | Trim |
| 8 | AVTX | Avalo Therapeutics Inc | +0.3% | +85.47% | Add |
| 9 | ANIK | Anika Therapeutics Inc | +0.2% | — | Unchanged |
| 10 | AGIO | Agios Pharmaceuticals Inc | — | — | Unchanged |
| 11 | VRCA | Verrica Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 12 | MAZE | Maze Therapeutics Inc | -0.7% | +11.77% | Add |
| 13 | EXEL | Exelixis Inc | -1.2% | — | Unchanged |
| 14 | ADMA | Adma Biologics Inc | -1.5% | +67.85% | Add |
| 15 | LQDA | Liquidia CORP | -2.7% | — | Unchanged |
| 16 | ABVX | Abivax Sa-adr | -5.3% | +0.69% | Add |
| 17 | MLYS | Mineralys Therapeutics Inc | -10.2% | -45.32% | Trim |
| 18 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 19 | SYRE | Spyre Therapeutics Inc | — | NEW | New buy |
| 20 | INBX | Inhibrx Biosciences Inc | — | EXIT | Sold out |
| 21 | LBRX | Lb Pharmaceuticals Inc | — | NEW | New buy |
| 22 | SABS | Sab Biotherapeutics Inc | — | NEW | New buy |
| 23 | IRD | Opus Genetics Inc | — | NEW | New buy |
| 24 | MBX | Mbx Biosciences Inc | — | NEW | New buy |
| 25 | RAPT | Rapt Therapeutics Inc | — | EXIT | Sold out |
| 26 | FTH | Faeth Therapeutics Inc | — | NEW | New buy |
| 27 | SPRB | Spruce Biosciences Inc | — | EXIT | Sold out |
| 28 | AURA | Aura Biosciences Inc | — | NEW | New buy |
| 29 | XLO | Xilio Therapeutics Inc | — | NEW | New buy |
| 30 | ELDN | Eledon Pharmaceuticals Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Caligan Partners LP reported a total U.S. public equity portfolio value of $2.1B across 26 disclosed positions in Q1 2026.
During Q1 2026, Caligan Partners LP's top holdings by market value included LQDA (20.4%)、RVMD (12.2%)、ABVX (10.8%). The largest single position, LQDA, represented 20.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
CGON
市值: $60.9M
Top Position Liquidated / Trimmed
INBX
前期市值: $37.4M
In Q1 2026, Caligan Partners LP made 25 total portfolio adjustments, initiating 9 new buys, adding to 10 positions, trimming 2 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.